I Sold My AMD Stock! Here’s Why:
1 extracted signal · 1 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 05 Aug 2026, 17:42 UTC
- Recorded by Tahlil Plus
- 05 Aug 2026, 18:28 UTC
AI-generated source summary
The analysis focuses on Advanced Micro Devices (AMD) and Nvidia (NVDA) stocks, suggesting bullish potential for both. AMD is currently trading at $518.58, with a target price of $600 and a failure bound at $475. The company's strong Q2 2026 earnings in its data center segment, showing a 107% year-over-year revenue growth and a significant increase in operating margin to 31%, are highlighted as key drivers. The speaker notes that AMD's P/E ratio is around 25x, which is considered reasonable for its growth, especially when compared to Nvidia, which trades at a higher multiple of approximately 58x to 20x depending on the earnings year. The speaker also points out Nvidia's strong year-over-year EPS growth (82% in Q2 2026) but suggests that at its current valuation, the upside potential might be limited compared to AMD. The analysis indicates that SpaceX's commitment to using Nvidia GPUs exclusively might not be enough to justify Nvidia's current valuation, leading to a preference for AMD due to its more attractive risk-reward profile and lower valuation multiples.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.